ImClone's (IMCL) Phase 2 Trial of IMC-A12 and IMC-1121B Open for Patient Enrollment
More News related to IMCL
- NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum
- Lilly Completes Cash Tender Offer for ImClone Systems
- ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
- Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
More News related to Corporate News
- Goldman Sachs Added Salesforce.com (CRM) to its Conviction Sell List
- KeyBanc Comments on Packaging Stocks, Downgrades PTV and SLGN
- Deutsche Bank's Mayo Slashes Estimates On Goldman Sachs and Morgan Stanley (GS, MS)
- Deutsche Bank's Mayo Cuts Estimates On Goldman Sachs and Morgan Stanley (GS, MS)
- Piper Jaffray Comments On Cheap Valuations In Aesthetic Space Following JNJ's Mentor (MNT) Takeover (CUTR, BFRM)
ImClone Systems Incorporated (NASDAQ: IMCL) today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment.
IMC-A12 and IMC-1121B are two therapeutic candidates in ImClone's proprietary receptor-targeted antibody pipeline. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody and IMC-1121B is its fully human, IgG1 anti-vascular growth factor receptor-2 monoclonal antibody.
This multicenter, randomized open-label Phase 2 single-arm study is enrolling patients with metastatic androgen-independent prostate cancer who have developed disease progression during or within 60 days of receiving docetaxel-based chemotherapy or demonstrated intolerance to docetaxel-based therapy. A total of 132 patients are expected to be enrolled at various centers, including those that participate in the Department of Defense's Prostate Cancer Consortium. This Phase 2 study is designed to evaluate the efficacy and safety of both IMC-A12 and IMC-1121B combined with mitoxantrone and prednisone. IMC-A12 and IMC-1121B are administered weekly, whereas mitoxantrone is administered every three weeks with oral daily prednisone.
ImClone Systems Incorporated, a biopharmaceutical company, engages in the development and commercialization of a portfolio of targeted treatments for the medical needs of patients with cancer in the United States and Canada.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
